Biomea Fusion(BMEA)
SAN CARLOS, CABiotechnology
Focus: Biomea Fusion is a clinical-stage biotech focused on small-molecule therapeutics targeting oncology and metabolic diseases, operating as a public company since 2017. The company maintains a lean operating model with a diversified pipeline across multiple indications.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Biomea Fusion
AI assessmentNot HiringNo open roles listed right now. Follow Biomea Fusion to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Biomea Fusion's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
BMF-219
Acute Myeloid LeukemiaClinical Trials (1)
NCT05153330Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1Help build intelligence for Biomea Fusion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.